Policy & Medicine July 29, 2020
Thomas Sullivan

The Federal Trade Commission (“FTC”) recently released its annual report for 2019. The FTC’s annual report details the FTC’s actions over the prior year. In 2019, similar to other years, the health care industry represented 46 percent of the FTC’s competition enforcement actions. That 46 percent was split between general health care (18 percent) and pharmaceuticals and medical devices (28 percent).

Report

As described in the FTC’s report, “The Commission has long prioritized competition in health care markets because such competition helps contain costs, improves quality, increases access, and encourages innovation. Relying primarily on enforcement, the Commission works to prevent anticompetitive mergers and conduct that would harm competition in these markets.”

The FTC describes its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Regulations
Opinion: STAT+: How AI can help satisfy FDA’s drug, device diversity requirements
FDA wants to boost trial innovation with new center at CDER
Stelara biosimilar from Alvotech, Teva approved by FDA
Scopio Labs Receives FDA Clearance For AI-Driven Bone Marrow Analysis Application
STAT+: Grocers are pushing legislation they claim would enhance food safety. Advocates say it would gut FDA rules

Share This Article